Hemolytic disease of the fetus and newborn (HDFN) does not discriminate by race or geographic location, meaning anyone, anywhere, can be impacted by the disease. Promoting diversity in HDFN research and treatment is key to improving patient outcomes for all.
Here are a few reasons why awareness and research of the effects of HDFN on patients from all walks of life is so important.
Differences in HDFN cause
HDFN occurs as a result of a mismatch between the blood of the mother and baby, which causes the mother to produce antibodies that attack the baby’s blood. Studies have shown that the type of mismatch may vary between populations, though.
Read more about HDFN causes and risk factors
To give a few examples, HDFN is most often attributed to the anti-D antibody among white and Indian individuals. Cases of HDFN caused by the anti-M antibody have also been observed, mainly in Asian individuals.
Knowing the most common causes of HDFN in different racial and ethnic groups can improve diagnosis by allowing for more targeted screening. It can also support the development of new protocols to help prevent future cases of HDFN.
Differences in HDFN prevalence
Current estimates suggest that HDFN affects different races and ethnicities at different rates.
Around 15% of white populations are impacted by HDFN, compared to 5% to 8% of Black populations and 1% to 2% of Asian and Native American populations. In certain Spanish and French groups, the prevalence of HDFN can be as high as 35%.
More research is needed to confirm the accuracy of these figures. There’s a chance that some racial and ethnic groups have even higher rates of HDFN, but cases are currently being underreported. If that’s the case, researchers and healthcare providers will need to work to improve outreach to those groups to ensure they have equitable access to care.
Barriers to care
In many high-income countries such as the United States, the burden of HDFN has been dramatically reduced in recent years. Even so, patients in certain areas still report difficulty finding specialists who are well-versed in the disease.
In resource-limited areas, barriers to care are often more severe. Global disparities in HDFN management remain a significant issue, from diagnosis to treatment and managing complications.
Many steps can be taken to break down these barriers and promote diverse representation in HDFN research and treatment:
- Improving diversity in clinical trials: Researchers should focus their recruitment efforts on creating diverse study populations that reflect real-world patient experiences.
- Breaking down language barriers: Employing multilingual healthcare providers or offering interpretation services can help improve patient outcomes.
- Practicing cultural competence: Researchers and providers must understand and respect cultural differences among their patients.
HDFN isn’t a monolith, and current practices must reflect that. Between the racial, genetic and socioeconomic differences among patients, future work should address and tackle the complexity of the disease head-on.
Sign up here to get the latest news, perspectives, and information about HDFN sent directly to your inbox. Registration is free and only takes a minute.
